Tafluprost

他氟前列素

Report date: 2022/01/14 13:23:58
NME

Base Information

Drug NameTafluprost
Drug Alias NameTafluprostum他氟前列腺素SaflutanZioptanTaflotan +[10] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionProstanoid FP receptor agonists
TargetsProstanoid FP receptor
Therapy Area/IndicationsGlaucoma, Open-AngleGlaucomaOcular Hypertension
Global Approved IndicationsGlaucoma, Open-AngleGlaucomaOcular Hypertension
Approved Indications in ChinaGlaucoma, Open-AngleOcular Hypertension
Original Approved Country/TerritoryGermany
Original Approved Date2008/03/01
Country/TerritoryUnited StatesGermanyEgypt +[7] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesSanten Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesThea Pharma IncLaboratoires Thea SASSanten Pharmaceutical Co Ltd +[4] 
Inactive CompaniesSanten OyAlexandria UniversityMerck Sharp & Dohme LLC
Active IndicationsGlaucoma, Open-AngleGlaucomaOcular Hypertension
Inactive IndicationsN/A

Other Information

ATC CodeS01EE05
Related LinksWikipediaDrugBankKEGG